Cabozantinib in progressive medullary thyroid cancer.

ABSTRACT:

Purpose

Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clinical activity in patients with medullary thyroid cancer (MTC) in phase I.

Patients and methods

We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiographic progression of metastatic MTC. Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo. The primary end point was progression-free survival (PFS). Additional outcome measures included tumor response rate, overall survival, and safety.

Results

The estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for pl

SUBMITTER: Elisei R 

PROVIDER: S-EPMC4164813 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature